AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6194944 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental education for parents
Number of subjects: 39
Study 6194944 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent education in child management
Number of subjects: 39
Study 6194944 — intervention group
Group type: COMPARATOR
Intervention: No-education control condition
Number of subjects: 39
Study 29601220 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived force at 25% MVC
Number of subjects: 30
Study 29601220 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived force at 50% MVC
Number of subjects: 30
Study 29601220 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived force at 75% MVC
Number of subjects: 30
Study 29601220 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-MVC performance
Number of subjects: 30
Study 29601220 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants familiar with exercise
Number of subjects: 30
Study 30019318 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab + FOLFOX4
Number of subjects: 528
Study 30019318 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4
Number of subjects: 528
Study 26729381 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to weekly cardiac rehabilitation (CR) exercise classes and information sessions.
Number of subjects: 41
Study 25073752 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined introducer tool and stylet technique
Number of subjects: 90
Study 25073752 — intervention group
Group type: COMPARATOR
Intervention: Digital manipulation technique
Number of subjects: 90
Study 25073752 — intervention group
Group type: COMPARATOR
Intervention: Introducer tool technique
Number of subjects: 90
Study 23115772 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary instruments
Number of subjects: 40
Study 23115772 — intervention group
Group type: COMPARATOR
Intervention: Hand instruments
Number of subjects: 40
Study 21173294 — intervention group
Group type: COMPARATOR
Intervention: 6 mL/kg/h of crystalloid (restrictive fluid strategy)
Number of subjects: 70
Study 21173294 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mL/kg/h of crystalloid (conservative fluid strategy)
Number of subjects: 70
Study 16278262 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral vitamin D doses of 1,400 IU (200 IU/d)
Number of subjects: 179
Study 16278262 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral vitamin D doses of 14,000 IU (2,000 IU/d)
Number of subjects: 179
Study 16278262 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 179
Study 14640932 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tazarotene monotherapy
Number of subjects: 0
Study 14640932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies (with steroids, calcipotriene, and phototherapy)
Number of subjects: 0
Study 14640932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study 11153016 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue 0.5 ml
Number of subjects: 218
Study 11153016 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue 1 ml
Number of subjects: 218
Study 11153016 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue 2 ml
Number of subjects: 218
Study 11153016 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue 4 ml
Number of subjects: 218
Study 11153016 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue (all doses)
Number of subjects: 218
Study 11153016 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue
Number of subjects: 218
Study 9160625 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depression with lifetime panic disorder
Number of subjects: 276
Study 9160625 — intervention group
Group type: COMPARATOR
Intervention: Major depression without lifetime panic disorder
Number of subjects: 276
Study 9160625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy and psychotherapy
Number of subjects: 276
Study 1423181 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (0.15 mg/kg)
Number of subjects: 45
Study 1423181 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (1 mg/kg)
Number of subjects: 45
Study 6229314 — intervention group
Group type: EXPERIMENTAL
Intervention: Health visitor intervention in urban practice
Number of subjects: 0
Study 31818841 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention (8 weeks, 9 modules)
Number of subjects: 352
Study 31818841 — intervention group
Group type: COMPARATOR
Intervention: Active control condition with a self-help manual
Number of subjects: 352
Study 29608839 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide treatment for 50 days
Number of subjects: 52
Study 29608839 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sulodexide)
Number of subjects: 52
Study 25920633 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 30
Study 25920633 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid (CS) injection
Number of subjects: 30
Study 23633757 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST) combined with behavioral sleep strategies
Number of subjects: 47
Study 23633757 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy (CT) combined with behavioral sleep strategies
Number of subjects: 47
Study 20689448 — intervention group
Group type: EXPERIMENTAL
Intervention: SDT-based intervention
Number of subjects: 221
Study 20689448 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate and vigorous exercise at 2 yr
Number of subjects: 221
Study 20689448 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-yr autonomous regulation
Number of subjects: 221
Study 20122585 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐Line AEP (AAI)
Number of subjects: 40
Study 20122585 — intervention group
Group type: COMPARATOR
Intervention: aepEX
Number of subjects: 40
Study 16950057 — intervention group
Group type: EXPERIMENTAL
Intervention: Marathon polyethylene liners (cross-linked with 5 Mrad gamma-irradiation and heat-treated)
Number of subjects: 0
Study 16950057 — intervention group
Group type: COMPARATOR
Intervention: Enduron polyethylene liners (non-cross-linked)
Number of subjects: 0
Study 16950057 — intervention group
Group type: EXPERIMENTAL
Intervention: Marathon polyethylene liners (cross-linked)
Number of subjects: 0
Study 15489865 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim (Granocyte)
Number of subjects: 98
Study 15489865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 12577369 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of composite Shendi Decoction (CSDD) and Diyin Tablet (DYT)
Number of subjects: 35
Study 12577369 — intervention group
Group type: COMPARATOR
Intervention: Composite Shendi Decoction (CSDD) alone
Number of subjects: 35
Study 12577369 — intervention group
Group type: COMPARATOR
Intervention: Diyin Tablet (DYT) alone
Number of subjects: 35
Study 9605804 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins
Number of subjects: 1075
Study 9605804 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 1075
Study 9605804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1075
Study 8029265 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine (150 mg/kg)
Number of subjects: 8
Study 8029265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8029265 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine (150 mg/kg) at 22 degrees C
Number of subjects: 8
Study 2557049 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartar control dentifrice formulation containing soluble pyrophosphates
Number of subjects: 0
Study 2557049 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 0
Study 4599121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephacetrile
Number of subjects: 0
Study 4599121 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 0
Study 29342060 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-infused highly cross-linked polyethylene (HXLPE/VitE) cup
Number of subjects: 62
Study 29342060 — intervention group
Group type: COMPARATOR
Intervention: Ultra-high molecular weight polyethylene (UHMWPE) cup
Number of subjects: 62
Study 28153933 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a falls prevention programme (video, workbook, individualised follow-up)
Number of subjects: 390
Study 28153933 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus a social visit
Number of subjects: 390
Study 26117292 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC 62.5 μg + FF/VI (100/25 μg)
Number of subjects: 1238
Study 26117292 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC 125 μg + FF/VI (100/25 μg)
Number of subjects: 1238
Study 26117292 — intervention group
Group type: COMPARATOR
Intervention: Placebo + FF/VI (100/25 μg)
Number of subjects: 1238
Study 23205521 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-face prime condition (participants exposed to videos of their own faces)
Number of subjects: 0
Study 23205521 — intervention group
Group type: COMPARATOR
Intervention: Nonself-face prime condition (participants exposed to faces of others)
Number of subjects: 0
Study 23205521 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-face prime condition (participants with high autism traits)
Number of subjects: 0
Study 21206307 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural motor cortex stimulation (MCS) with a new octopolar lead
Number of subjects: 6
Study 18422412 — intervention group
Group type: EXPERIMENTAL
Intervention: Online family problem‐solving (OFPS) intervention
Number of subjects: 150
Study 18422412 — intervention group
Group type: COMPARATOR
Intervention: Internet resource intervention (IRI)
Number of subjects: 150
Study 16494632 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PLLA treatment
Number of subjects: 30
Study 16494632 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed PLLA treatment
Number of subjects: 30
Study 16494632 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed treatment)
Number of subjects: 30
Study 12621597 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 57
Study 11780993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-containing bioadhesive patch (L-BP)
Number of subjects: 60
Study 11780993 — intervention group
Group type: COMPARATOR
Intervention: Benzocaine-containing gel (B-G)
Number of subjects: 60
Study 11780993 — intervention group
Group type: COMPARATOR
Intervention: Needlestick injections with anesthetic
Number of subjects: 60
Study 11780993 — intervention group
Group type: COMPARATOR
Intervention: 25- and 27-gauge needles
Number of subjects: 60
Study 9440907 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (0.15 IU/kg/day s.c.) for 1 year
Number of subjects: 17
Study 9440907 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GH treatment)
Number of subjects: 17
Study 8493626 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (400 micrograms) inhaled four times daily for 24 weeks
Number of subjects: 64
Study 8493626 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaled four times daily for 24 weeks
Number of subjects: 64
Study 3371081 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (550 mg initial dose, then 275 mg as needed, max 5 doses/day for 3 days)
Number of subjects: 54
Study 3371081 — intervention group
Group type: COMPARATOR
Intervention: Dihydrocodeine tartrate (30 mg initial dose, then 30 mg as needed, max 5 doses/day for 3 days)
Number of subjects: 54
Study 31691827 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol
Number of subjects: 0
Study 31691827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29861241 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual training sessions
Number of subjects: 82
Study 29861241 — intervention group
Group type: EXPERIMENTAL
Intervention: Group training sessions
Number of subjects: 82
Study 29861241 — intervention group
Group type: EXPERIMENTAL
Intervention: Training sessions (3rd, 4th, and 5th)
Number of subjects: 82
Study 24237482 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Relationships videoconferencing group intervention (HR-VG)
Number of subjects: 71
Study 24237482 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 71
Study 22269534 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg MDMA
Number of subjects: 61
Study 22269534 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.42 mg/kg methamphetamine
Number of subjects: 61
Study 22269534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 20039172 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (2.5 mg/day, uptitrated to 10 mg/day)
Number of subjects: 120
Study 20039172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 17362710 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (20 microg of ethinyl estradiol/100 mg of levonorgestrel)
Number of subjects: 76
Study 17362710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 15952551 — intervention group
Group type: EXPERIMENTAL
Intervention: Brackets bonded 4 mm from the intact incisal edge
Number of subjects: 40
Study 15952551 — intervention group
Group type: COMPARATOR
Intervention: Bracket position determined individually by transferring the maximum embrasure difference to the bracket slot height difference
Number of subjects: 40
Study 12221216 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g fructose fed 60 min before the potato meal
Number of subjects: 31
Study 12221216 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g fructose fed 30 min before the potato meal
Number of subjects: 31
Study 12221216 — intervention group
Group type: COMPARATOR
Intervention: 50 g available carbohydrate from instant mashed potatoes (control)
Number of subjects: 31
Study 9706927 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine (15 mg) with morphine sulfate (0.2 mg)
Number of subjects: 30
Study 9706927 — intervention group
Group type: COMPARATOR
Intervention: Hypobaric bupivacaine (15 mg) with morphine sulfate (0.2 mg)
Number of subjects: 30
Study 8581394 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy with recombinant human GM-CSF (rhGM-CSF)
Number of subjects: 12
Study 8581394 — intervention group
Group type: COMPARATOR
Intervention: Standard doses of chemotherapy without rhGM-CSF
Number of subjects: 12
Study 2533678 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine 0.5%
Number of subjects: 20
Study 481976 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (50 mg/kg intramuscularly during days 1 to 3 of life)
Number of subjects: 40
Study 31151343 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous disc decompression with coblation nucleoplasty (PDCN)
Number of subjects: 74
Study 27644475 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate extract (PE) 1000 mg
Number of subjects: 19
Study 27644475 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 19
Study 26543359 — intervention group
Group type: EXPERIMENTAL
Intervention: Zabofloxacin (367 mg once daily for 5 days)
Number of subjects: 345
Study 26543359 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg once daily for 7 days)
Number of subjects: 345
Study 23947742 — intervention group
Group type: EXPERIMENTAL
Intervention: PEMF therapy
Number of subjects: 40
Study 23947742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21704212 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 21704212 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle therapy
Number of subjects: 0
Study 20027368 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoten
Number of subjects: 0
Study 17977787 — intervention group
Group type: EXPERIMENTAL
Intervention: H1-coil
Number of subjects: 32
Study 17977787 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-coil
Number of subjects: 32
Study 17977787 — intervention group
Group type: COMPARATOR
Intervention: Standard figure-8 coil
Number of subjects: 32
Study 17977787 — intervention group
Group type: COMPARATOR
Intervention: Sham-coil control
Number of subjects: 32
Study 16649053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure dressing
Number of subjects: 96
Study 16649053 — intervention group
Group type: COMPARATOR
Intervention: No dressing (exposed wounds)
Number of subjects: 96
Study 12809167 — intervention group
Group type: EXPERIMENTAL
Intervention: Acylated ghrelin (1.0 microg/kg i.v. at 0 min)
Number of subjects: 7
Study 12809167 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-acylated ghrelin
Number of subjects: 7
Study 12809167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 10528035 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily for 52 weeks
Number of subjects: 143
Study 7853592 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal incision (TAI)
Number of subjects: 145
Study 7853592 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneal incision (RPI)
Number of subjects: 145
Study 1951300 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid administered pre-ECC
Number of subjects: 17
Study 1951300 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid administered post-ECC
Number of subjects: 17
Study 6128875 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EAP)
Number of subjects: 18
Study 6128875 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Manual Acupuncture (TMA)
Number of subjects: 18
Study 6128875 — intervention group
Group type: COMPARATOR
Intervention: Sham Electroacupuncture (SEAP)
Number of subjects: 18
Study 30658275 — intervention group
Group type: EXPERIMENTAL
Intervention: GermanIMPACT (intervention group)
Number of subjects: 246
Study 30658275 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 246
Study 27951475 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position during spontaneous breathing
Number of subjects: 9
Study 27951475 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirecumbent position during spontaneous breathing
Number of subjects: 9
Study 27951475 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position during spontaneous breathing
Number of subjects: 9
Study 27951475 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation (all positions)
Number of subjects: 9
Study 25133646 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC) twice a week
Number of subjects: 80
Study 25133646 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC) whole week
Number of subjects: 80
Study 23083416 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Intervention (MI)
Number of subjects: 142
Study 23083416 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 142
Study 21166843 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c) ≥ 6.5% (≥ 48 mmol/mol)
Number of subjects: 522
Study 21166843 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c) ≥ 6.0% (≥ 42 mmol/mol)
Number of subjects: 522
Study 21166843 — intervention group
Group type: COMPARATOR
Intervention: Diagnosis based on two consecutive oral glucose tolerance tests
Number of subjects: 522
Study 18058810 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan with thalidomide (200 mg/day, increased as tolerated)
Number of subjects: 69
Study 18058810 — intervention group
Group type: COMPARATOR
Intervention: Topotecan alone
Number of subjects: 69
Study 18058810 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan with thalidomide
Number of subjects: 69
Study 16925692 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (80/4.5 microg, two inhalations twice daily)
Number of subjects: 630
Study 16925692 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (100 microg, two inhalations twice daily)
Number of subjects: 630
Study 16925692 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (100 microg, two inhalations twice daily) and formoterol (4.5 microg, two inhalations twice daily) in separate inhalers
Number of subjects: 630
Study 12968985 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (30 mg intravenous bolus followed by 1.0 or 1.25 mg/kg subcutaneously twice a day)
Number of subjects: 448
Study 10839911 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 40
Study 10839911 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 40
Study 9332966 — intervention group
Group type: EXPERIMENTAL
Intervention: Guía plus mood management intervention (Tomando Control de su Vida)
Number of subjects: 136
Study 1596501 — intervention group
Group type: EXPERIMENTAL
Intervention: Se-rich bread providing 100 micrograms Se daily for 6 weeks
Number of subjects: 18
Study 1596501 — intervention group
Group type: EXPERIMENTAL
Intervention: Se-rich bread providing 200 micrograms Se daily for 6 weeks
Number of subjects: 18
Study 1596501 — intervention group
Group type: EXPERIMENTAL
Intervention: Se-rich bread providing 300 micrograms Se daily for 6 weeks
Number of subjects: 18
Study 3880521 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil (400 mg daily)
Number of subjects: 44
Study 3880521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 29562927 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 minutes/week of aerobic exercise (MODERATE)
Number of subjects: 400
Study 29562927 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 minutes/week of aerobic exercise (HIGH)
Number of subjects: 400
Study 29562927 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MODERATE and HIGH groups
Number of subjects: 400
Study 27716172 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% tofacitinib QD
Number of subjects: 435
Study 27716172 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% tofacitinib BID
Number of subjects: 435
Study 27716172 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tofacitinib QD
Number of subjects: 435
Study 27716172 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% tofacitinib QD and BID, 1% tofacitinib BID
Number of subjects: 435